These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 23692839)

  • 1. Atypical hemolytic uremic syndrome due to factor H autoantibody.
    Uslu-Gökceoğlu A; Doğan CS; Comak E; Koyun M; Akman S
    Turk J Pediatr; 2013; 55(1):86-9. PubMed ID: 23692839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.
    Lee BH; Kwak SH; Shin JI; Lee SH; Choi HJ; Kang HG; Ha IS; Lee JS; Dragon-Durey MA; Choi Y; Cheong HI
    Pediatr Res; 2009 Sep; 66(3):336-40. PubMed ID: 19531976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The autoimmune disease DEAP-hemolytic uremic syndrome.
    Skerka C; Zipfel PF; Müller D; Micklisch S; Riedl M; Zimmerhackl LB; Hofer J
    Semin Thromb Hemost; 2010 Sep; 36(6):625-32. PubMed ID: 20865639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies in haemolytic uraemic syndrome (HUS).
    Skerka C; Józsi M; Zipfel PF; Dragon-Durey MA; Fremeaux-Bacchi V
    Thromb Haemost; 2009 Feb; 101(2):227-32. PubMed ID: 19190803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency.
    Józsi M; Licht C; Strobel S; Zipfel SL; Richter H; Heinen S; Zipfel PF; Skerka C
    Blood; 2008 Feb; 111(3):1512-4. PubMed ID: 18006700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of DEAP-HUS with eculizumab.
    Noone D; Waters A; Pluthero FG; Geary DF; Kirschfink M; Zipfel PF; Licht C
    Pediatr Nephrol; 2014 May; 29(5):841-51. PubMed ID: 24249282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome.
    Zipfel PF; Mache C; Müller D; Licht C; Wigger M; Skerka C;
    Pediatr Nephrol; 2010 Oct; 25(10):2009-19. PubMed ID: 20157737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.
    Hofer J; Janecke AR; Zimmerhackl LB; Riedl M; Rosales A; Giner T; Cortina G; Haindl CJ; Petzelberger B; Pawlik M; Jeller V; Vester U; Gadner B; van Husen M; Moritz ML; Würzner R; Jungraithmayr T;
    Clin J Am Soc Nephrol; 2013 Mar; 8(3):407-15. PubMed ID: 23243267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T.
    Waters AM; Pappworth I; Marchbank K; Bockenhauer D; Tullus K; Pickering MC; Strain L; Sebire N; Shroff R; Marks SD; Goodship TH; Rees L
    Am J Transplant; 2010 Jan; 10(1):168-72. PubMed ID: 19951285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome.
    Strobel S; Hoyer PF; Mache CJ; Sulyok E; Liu WS; Richter H; Oppermann M; Zipfel PF; Józsi M
    Nephrol Dial Transplant; 2010 Jan; 25(1):136-44. PubMed ID: 19666655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies.
    Boyer O; Balzamo E; Charbit M; Biebuyck-Gougé N; Salomon R; Dragon-Durey MA; Frémeaux-Bacchi V; Niaudet P
    Am J Kidney Dis; 2010 May; 55(5):923-7. PubMed ID: 20202729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
    Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
    Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS.
    Dragon-Durey MA; Blanc C; Garnier A; Hofer J; Sethi SK; Zimmerhackl LB
    Semin Thromb Hemost; 2010 Sep; 36(6):633-40. PubMed ID: 20865640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS.
    Hackl A; Ehren R; Kirschfink M; Zipfel PF; Beck BB; Weber LT; Habbig S
    Pediatr Nephrol; 2017 Jun; 32(6):1081-1087. PubMed ID: 28220235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
    Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J
    Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome.
    Abarrategui-Garrido C; Martínez-Barricarte R; López-Trascasa M; de Córdoba SR; Sánchez-Corral P
    Blood; 2009 Nov; 114(19):4261-71. PubMed ID: 19745068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment.
    Hofer J; Giner T; Józsi M
    Semin Thromb Hemost; 2014 Jun; 40(4):431-43. PubMed ID: 24799303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
    Poolpol K; Orth-Höller D; Speth C; Zipfel PF; Skerka C; de Córdoba SR; Brockmeyer J; Bielaszewska M; Würzner R
    Mol Immunol; 2014 Mar; 58(1):77-84. PubMed ID: 24317278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activation in diseases presenting with thrombotic microangiopathy.
    Meri S
    Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3.
    Kopp A; Strobel S; Tortajada A; Rodríguez de Córdoba S; Sánchez-Corral P; Prohászka Z; López-Trascasa M; Józsi M
    J Immunol; 2012 Aug; 189(4):1858-67. PubMed ID: 22786770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.